Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Stryker Corporation    SYK

STRYKER CORPORATION

(SYK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

STRYKER CORP : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)

11/23/2020 | 04:34pm EST

ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

On November 23, 2020, Stryker Corporation (the "Company") completed a public offering (the "Offering") of $600,000,000 aggregate principal amount of the Company's 0.600% Notes due 2023 (the "Notes").

The Notes were sold pursuant to an Underwriting Agreement, dated November 18, 2020 (the "Underwriting Agreement"), among the Company and Citigroup Global Markets Inc., BofA Securities, Inc. and Wells Fargo Securities, LLC, as underwriters. The Offering was made pursuant to the Company's Automatic Shelf Registration Statement on Form S-3 (File No. 333-229539) and the Prospectus included therein, filed with the Securities and Exchange Commission on February 7, 2019, and supplemented by the Prospectus Supplement dated November 18, 2020.

The Notes were issued under an Indenture, dated January 15, 2010 (the "Base Indenture"), between the Company and U.S. Bank National Association, as trustee (the "Trustee"), as supplemented by the Twenty-Fifth Supplemental Indenture, dated November 23, 2020, between the Company and the Trustee (the "Supplemental Indenture," and the Base Indenture as so supplemented, the "Indenture").

The Notes will bear interest at a rate of 0.600% per year. Interest on the Notes is payable on each June 1 and December 1, commencing on June 1, 2021. The Notes will mature on December 1, 2023.

Prior to December 1, 2021, the Company may redeem the Notes at the Company's option for cash, any time in whole or from time to time in part, at a redemption price that includes accrued and unpaid interest and the applicable make-whole premium, as specified in the Indenture. However, no make-whole premium will be paid for redemption of the Notes on or after December 1, 2021.

The Company expects to receive net proceeds of approximately $596 million, after deducting the underwriting discount and estimated expenses related to the Offering. The Company intends to use the net proceeds from the Offering for general corporate purposes, which may include payments in connection with the redemption of Wright Medical Group N.V.'s ("Wright") convertible debt, which the Company assumed upon completion of the acquisition of Wright.

The Company may issue additional debt from time to time pursuant to the Indenture. The Indenture contains covenants that limit the Company's ability to, among other things, incur certain liens securing indebtedness, engage in certain sale and leaseback transactions, and enter into certain consolidations, mergers, conveyances, transfers or leases of all or substantially all of the Company's assets. Subject to certain limitations, in the event of the occurrence of both (1) a change of control of the Company and (2) a downgrade of the Notes below investment grade rating by both Moody's Investors' Services, Inc. and Standard & Poor's Ratings Services within a specified time period, the Company will be required to make an offer to purchase the Notes at a price equal to 101% of the principal amount of the Notes, plus accrued and unpaid interest to, but not including, the date of repurchase.

The foregoing description of the Underwriting Agreement, Base Indenture and the Supplemental Indenture does not purport to be complete and is qualified in its entirety by reference to the full text of such documents, which are filed as Exhibits 1.1, 4.1 and 4.2 hereto, respectively, and incorporated herein by reference.

ITEM 2.03 CREATION OF A DIRECT FINANCIAL OBLIGATION OR AN OBLIGATION UNDER AN

OFF-BALANCE SHEET ARRANGEMENT OF A REGISTRANT

The information set forth in Item 1.01 above with respect to the Notes is hereby incorporated by reference into this Item 2.03, insofar as it relates to the creation of a direct financial obligation.

--------------------------------------------------------------------------------

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS




Exhibit
  No.                                    Description

 1.1          Underwriting Agreement, dated November 18, 2020, between Stryker
            Corporation and Citigroup Global Markets Inc., BofA Securities, Inc.
            and Wells Fargo Securities, LLC, as underwriters.

 4.1          Indenture, dated January 15, 2010, between Stryker Corporation and
            U.S. Bank National Association, as trustee (incorporated by reference
            to Exhibit 4.1 to the Company's Current Report on Form 8-K, dated
            January 15, 2010 (Commission File No. 000-09165)).

 4.2          Twenty-Fifth Supplemental Indenture (including the form of the
            note), dated November 23, 2020, between Stryker Corporation and U.S.
            Bank National Association, as trustee.

 5.1          Opinion of Sullivan & Cromwell LLP regarding the validity of the
            Notes.

 5.2          Opinion of Warner Norcross + Judd LLP regarding the validity of the
            Notes.

23.1          Consent of Sullivan & Cromwell LLP (included as part of Exhibit
            5.1).

23.2          Consent of Warner Norcross + Judd LLP (included as part of Exhibit
            5.2).

104         Cover Page Interactive Data File (the cover page XBRL tags are
            embedded within the Inline XBRL document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about STRYKER CORPORATION
01/07STRYKER : UBS Adjusts Stryker's Price Target to $250 From $215, Maintains Neutra..
MT
01/06STRYKER : Credit Suisse Adjusts Stryker's Price Target to $278 from $253, Keeps ..
MT
01/05STRYKER : Buys Medical Sensor Maker OrthoSensor for Unspecified Sum
MT
01/05Stryker acquires OrthoSensor
GL
01/04Stryker to host conference call on January 27, 2021
GL
2020STRYKER : BTIG Research Adjusts Stryker PT to $252 From $234, Maintains Buy Rati..
MT
2020STRYKER CORPORATION : Ex-dividend day for
FA
2020INSIDER TRENDS : Stryker Corp Insider Sale Scales Back 90-Days of Buys
MT
2020STRYKER : FTC Approves Conditions on Stryker's Acquisition of Wright Medical
DJ
2020STRYKER : Goldman Sachs Adjusts Stryker PT to $246 From $194, Maintains Sell Rat..
MT
More news